In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The safety and effectiveness of Detectnet have not been established in pediatric patients. Advise a pregnant woman of the potential risks of fetal exposure to radiation from administration of Detectnet.Īdvise a lactating woman to interrupt breastfeeding for 12 hours after Detectnet administration in order to minimize radiation exposure to a breastfed infant For patients on short-acting somatostatin analogs, a washout period of 2 days is recommended prior to imaging.Īll radiopharmaceuticals, including Detectnet, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. For patients on long-acting somatostatin analogs, a wash-out period of 28 days is recommended prior to imaging. Image patients just prior to dosing with somatostatin analogs. Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2). In published trials nausea immediately after injection was observed. In clinical trials, adverse reactions occurred at a rate of < 2% and included nausea, vomiting and flushing. uncinate process of the pancreas).Ī negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease. Increased uptake might also be seen in other non-cancerous pathologic conditions that express somatostatin receptors including thyroid disease or in subacute inflammation, or might occur as a normal physiologic variant (e.g. The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors. Advise patients to hydrate before and after administration and to void frequently after administration. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Long-term cumulative radiation exposure is associated with an Somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.ĭiagnostic radiopharmaceuticals, including Detectnet, contribute to a patient’s overall long-term cumulative radiation exposure. We are pleased the NCCN members have updated their Clinical Practice Guidelines to reflect the important clinical utility of Detectnet.”ĭetectnet is indicated for use with positron emission tomography (PET) for localization of Further, the 12.7 hour half-life of Detectnet enables it to be produced centrally and shipped to sites throughout the U.S, which is particularly important as we continue to navigate through the pandemic. “The Phase III results demonstrate the high sensitivity, specificity, and accuracy of Detectnet. “Neuroendocrine cancer continues to be an area of research for RadioMedix,” said Ebrahim Delpassand, MD, CEO of RadioMedix. Our unique manufacturing and distribution capabilities allow us to provide a reliable supply of Detectnet to physicians and imaging centers serving neuroendocrine patients regardless of geography.” “This agent is the only ready-made PET somatostatin receptor targeted diagnostic widely available throughout the U.S. “We are grateful that the NCCN acted quickly to include Detectnet in their Clinical Practice Guidelines in Oncology – Neuroendocrine and Adrenal Tumors,” said Curium Vice President of Marketing, North America, Michael Patterson. While Transitional Pass-Through Status remains in effect for Detectnet, C9068 was replaced with A9592 beginning April 1, 2021. Effective April 1, 2021, all sites of care will use code A9592 to submit for reimbursement for all patients. This information follows the recent news that the Centers for Medicare & Medicaid Services (CMS) has simplified the coding for Detectnet. Detectnet is a positron emission tomography (PET) agent indicated for the localization of somatostatin receptor positive neuroendocrine tumors in adults. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology – Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs). Louis, MO – May 5, 2021) – RadioMedix Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |